The perennial problem of trials such as this from ICL and those funded
by the Medical Research Council is that they do not use well defined
which can negate the research results.
To replicate a research study the patient samples used and
the methodology have to be the same and in this case it appears that
there are differences in both compared to the study published online 8
October, 2009 by the Science magazine.
The organisations in USA who discovered the XMRV retrovirus used the
Canadian Guidelines to select patients for their research and Invest in
ME feel the Canadian Guidelines should be used for all research.
Those who portray ME as a somatoform illness are fully aware that using
patients who do not fit strict selection criteria will obviously skew
results. We therefore have serious doubts about the the results of the
If the correct patient cohorts are not participating in the trials or
different methods are used then this will affect the results.
The result of finding no sign of XMRV would point to a different
methodology to that used in the research published by the Science magazine
in which 3.7% of
controls tested positive.
The work performed by the Whittemore-Peterson Institute (WPI) and the
National Cancer Institute and the Cleveland Clinic is of the highest
quality and has been validated by Science magazine.
Much more research is underway and the results from the first XMRV
replication trials such as these from ICL prove little.
People with ME and their families should expect these “false” results to
be publicised early, especially as ME has been ignored by the government
and research organisations for generations. However, the new XMRV
research has changed the landscape for good and patients and carers can
look forward to a new era of ME/CFS research based on the biomedical
basis for the illness.
Proper science is now finally being performed.
Those who have delayed or stopped high quality biomedical research into
ME from being performed in the past, and those who continue to downplay
the significance of the new research from WPI, will not be in a position
to continue this denial for much longer.
The WPI have promised more exciting news which we can expect to hear at
the forthcoming 5th Invest in ME International ME/CFS
Conference on 24th May in London.
Invest in ME remain convinced that the WPI research is of monumental
importance to the future of research into ME and we look forward to the
future and the momentum in biomedical research into ME which the XMRV
research has generated.
Invest in ME
The BBC article is available -
The PLoS One article
A statement from the Whittemore-Peterson Institute -